Molecular and Cellular Oncology Research Program

分子和细胞肿瘤学研究计划

基本信息

批准号：
10712119
负责人：
RINA PLATTNER
金额：
$ 22.5万
依托单位：
UNIVERSITY OF KENTUCKY
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-07-08 至 2028-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10712119
关键词：
Address Adhesions Agriculture Area Arts Automobile Driving Bioenergetics Biogenesis Biology Cancer Burden Cancer Center Cancer Center Support Grant Cancer Control Caregivers Catchment Area Cell Proliferation Cell Survival Chromatin Clinic Clinical Trials Collaborations Colorectal Cancer Communication Community Outreach DNA Repair Development Direct Costs Disparity Education Electronics Engineering Ensure Environment Enzymes Epigenetic Process Epithelium Extracellular Matrix Proteins FASN gene FDA approved Food Funding Future Genetic Genomic Instability Goals Heart Injuries Incidence Interdisciplinary Study Intervention Invaded Joints Kentucky Leadership Maintenance Malignant - descriptor Malignant Neoplasms Manuscripts Medicine Mesenchymal Metabolic Metabolism Mission Mitochondria Modeling Molecular NCI Center for Cancer Research Neoplasm Metastasis Normal tissue morphology Oncogenic Oxidation-Reduction Pathway interactions Patients Peer Review Phosphoric Monoester Hydrolases Phosphotransferases Population Prevention Production Productivity Protein Kinase Protein phosphatase Publications Publishing Reactive Oxygen Species Recurrence Regulation Research Research Personnel Research Priority Resistance Science Signal Transduction Signaling Molecule Specialist Stress Survivors Tissues Toxic effect Translating Treatment Efficacy Universities Vulnerable Populations base cancer cell cancer health disparity cancer initiation cancer prevention cancer stem cell cancer therapy cellular oncology clinical translation college community engagement diagnostic biomarker epigenetic regulation extracellular vesicles faculty mentor immune checkpoint blockade inter-institutional melanoma member microbiome molecular oncology mortality multidisciplinary neoplastic cell novel novel therapeutic intervention oncology program programs recruit stem cell biology therapeutic target therapy resistant tissue injury translational oncology translational pipeline tumor tumor immunology tumor initiation tumor metabolism tumor microenvironment tumor progression

项目摘要

PROJECT SUMMARY/ABSTRACT The goal of the Molecular and Cellular Oncology (MCO) Research Program is to gain a comprehensive understanding of basic mechanisms driving cancer initiation, progression, metastasis and therapeutic resistance to facilitate development of novel and rational approaches for cancer prevention and therapy. MCO research efforts are central to the overall Markey Cancer Center (MCC) mission to reduce the cancer burden with a focus on Kentucky and its most vulnerable populations through research, prevention, treatment, education and community engagement. MCO investigators determine signaling, genetic, epigenetic and metabolic mechanisms that promote cancer development, fuel tumor progression and contribute to therapeutic resistance. To achieve its goal, MCO proposes three inter-related aims: 1) Identify aberrant signaling networks and critical interactions of tumor cells with their microenvironment to delineate molecular mechanisms that drive tumor initiation, progression and metastasis and resistance; 2) Determine the contribution of metabolic reprogramming and epigenetic dysregulation to define novel pathways promoting cancer cell survival and adaptation; 3) Delineate the mechanisms by which dysregulation of redox signaling promotes genomic instability, therapeutic resistance and normal tissue toxicity. The 54 members of the MCO Program are experts in cancer cell signaling, tumor microenvironment, cancer metabolism, epigenetic regulation and redox biology who hail from 16 departments in the Colleges of Medicine; Engineering; Arts and Sciences; and Agriculture, Food and Environment, reflecting diverse disciplinary perspectives. Cancer-related MCO funding is nearly $10.3M in annual direct costs, and 53% of MCO peer-reviewed funding is from the NCI. Members have published 320 manuscripts (July 2018–June 2022), of which 106 (33%) are inter-programmatic, 81 (25%) are intra-programmatic, and 195 (61%) are inter-institutional. The program is co-led by three researchers with expertise in each of the three programmatic areas. Dr. Rina Plattner (an expert in oncogenic kinase signaling and tumor metastasis), Dr. Binhua “Peter” Zhou (a specialist in epigenetic and metabolic reprogramming of epithelial-mesenchymal transition) and Dr. Tianyan Gao (an expert in protein phosphatases and mitochondrial regulation of cancer stem cells) bring together expertise in cancer signaling (Plattner, Aim 1), epigenetics and metabolism (Zhou, Aim 2) and redox biology and mitochondrial bioenergetics (Gao, Aim 3). In addition to their scientific leadership, each offers significant strengths in clinical translation, junior faculty mentoring, communications among MCC Research Programs and expertise on populations within the MCC catchment area. By leveraging comprehensive program strengths, the MCO Program collectively provides a rich environment to facilitate multidisciplinary collaboration and builds a productive pipeline for translation of MCO science into the clinic.

项目摘要/摘要分子和细胞肿瘤学（MCO）研究计划的目标是获得全面的了解推动癌症开始，进步和转移和治疗的基本机制抵抗促进癌症预防和治疗的新颖和理性方法的发展。研究敌方是整个Markey癌症中心（MCC）任务的核心，以减轻癌症负担专注于肯塔基州，是通过研究，预防，治疗，教育和社区参与。促进癌症发展，燃料肿瘤进展和对治疗的贡献的代谢机制阻力。肿瘤细胞与微环境的关键相互作用，以描绘分子机制驱动肿瘤的启动，进展和抗性； 2）确定代谢的贡献重音仪和表观遗传失调，以定义促进癌细胞存活和的新途径适应； 3）描述氧化还原信号失调的机制 Instablity，治疗性耐药性和正常的组织TOXIAL。在癌细胞信号传导中来自16个部门的工程学；食物和环境，反映了与癌症相关的多样化的观点。 NCI为1030万美元的直接成本，其中53％的MCO同行评审资金是NCI。出版了320个手稿（2018年7月 - 2022年），其中106个（33％）是程序间的，81（25％）为杂志内和195（61％）是互联网的。三个三个程序化领域的专业知识（致癌激酶信号的专家（和肿瘤转移），Binhua博士“ Peter” Zhou（表观遗传和代谢重编程专家）上皮 - 间质转变）和Tianyan Gao博士（蛋白质磷酸盐和mitchondrial的专家癌症干细胞的调节）将癌症信号传导的专业知识汇总在一起（Plattner，AIM 1），表观遗传学和代谢（Zhou，AIM 2）和氧化还原生物学和线粒体生物能力（GAO，AIM 3）。科学领导力，每个人都在临床翻译，初级教师指导中提供了重要的优势优势， MCC研究计划之间的沟通和MCC集水区内人口的专业知识领域。促进多学科合作的环境，并建立一条富有成效的MCO的管道科学进入诊所。